Sterivet Laboratories Ltd said the U.S.Food and Drug Administration granted expedited review statusfor its proprietary drug Navicon.    The company said future marketability of Navicon in theU.S. will be greatly facilitated by receiving expedited reviewstatus and the company should achieve wide penetration once FDAapproval for the drug is received.    Navicon is a drug designed to treat navicular disease whichaffects the feet of one-third of all horses aged between fiveand 15. Reuter&#3;